Promising Lilly cancer drug fails in disappointing trial, shares fall 3 percent
Analysts had predicted that Lartruvo could eventually ring up as much as $600 million in annual sales. Eli Lilly and Co. now says it will suspend promotion of the drug.
Health Care Businesses
Articles
Walmart to leave CVS pharmacy network
The dispute between the world’s largest retail chain and the prominent pharmacy-benefits manager could roil the business of filling prescriptions.
Lilly to disclose more information about drug pricing
Eli Lilly and Co. won’t put the price of its prescription drugs in television ads, as the Trump administration has called for pharmaceutical companies to do, but will begin promoting a website where prices are available.
Lilly execs: $8B acquisition feeds into cancer drug strategy
Drug industry analysts on Monday applauded Eli Lilly and Co.’s pending $8 billion cash deal to buy a startup that focuses on oncology, which has become a prime focus for the pharma giant in the last year.
Big pharma stocks among top performers in 2018
Pharmaceutical giants Merck & Co. and Pfizer Inc. were kings of the Dow Jones industrial index during the year, while Eli Lilly and Co. was among the 20 largest gainers on the S&P 500.
Trump Medicare plan targets drugs from Eli Lilly, others
Makers of antidepressants and antipsychotics like Indianapolis-based Eli Lilly and Co., AstraZeneca, Pfizer, Allergan, Bausch Health and Otsuka Holdings might face new challenges and may be deterred from price hikes.
Rising fear among Asians leads Eli Lilly to rethink employee groups
New employees at Eli Lilly and Co. get a letter encouraging them to join one of the pharmaceutical firm’s affinity groups. There’s one for African Americans, one for Latino employees—and four for Asians.
Eli Lilly considering sale of China assets to raise cash
Indianapolis-based Lilly is working with advisers to gauge interest in selling off a selection of older drugs for antibiotics and central nervous system diseases in China.
Lilly raises guidance after topping profit, revenue expectations
Lilly’s revenue in the United States rose 11 percent year-over-year, to $3.4 billion, thanks largely to rising sales of diabetes drugs Trulicity and Basgalar, cancer treatment Verzenio and psoriasis medication Taltz.
Eli Lilly partner urges investors to look beyond biotech turmoil
Look at the future prospects, not the losses, says the CEO of a newly listed Chinese biotech company that’s developing anti-cancer drugs with Indianapolis-based Eli Lilly and Co.
Trump focusing on drug prices, high among voters’ concerns
President Donald Trump is linking the drug prices Americans complain about to one of his longstanding grievances: foreign countries the president says are taking advantage of U.S. research breakthroughs.
Opioid alternative from Lilly, Pfizer shows promise in study
The experimental drug eased arthritis pain in hard-to-treat patients without major safety concerns, a key step in creating a new class of medications that may one day offer an alternative to narcotics.
Endocyte acquisition gives Novartis key therapy—at almost 200 times its last price
One year ago, Indiana-based Endocyte Inc. bought the rights to a prostate cancer treatment for $12 million, plus future considerations. On Thursday, Novartis AG agreed to pay almost 200 times that amount to acquire Endocyte and the experimental therapy.
Firm planning $25M behavioral health hospital in Plainfield
The standalone, two-story facility is expected to offer a wide array of inpatient and outpatient services, including addiction treatment, counseling and psychiatric intensive care.
Elanco shares lowest since IPO after failing to get consensus buy rating
Shares in Elanco Animal Health Inc. slipped as much as 3.3 percent Monday morning after lead managers and other banks involved in its recent initial public offering started coverage on the animal health company.
Lilly might market diabetes drug for obesity after research results
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
Roche using data-driven diagnostic tools to reshape patient care
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
Big gymnasium in downtown corporate campus to be demolished
The owner of the 40,000-square-foot gym says upgrading the facility would cost tens of millions of dollars, and that the cost to maintain it is greater than the property’s value.
Migraine drug from Eli Lilly approved by FDA
Eli Lilly and Co. received clearance Thursday from U.S. regulators for a new migraine drug that will be the third in a promising class of therapies for patients who suffer from the recurrent, painful headaches.
Lilly’s Elanco animal-health business raises $1.5 billion in IPO
Greenfield-based Elanco Animal Health Inc. raised more than expected in its initial public offering, pricing its shares above the marketed price range.